Argenx (ARGX) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Argenx, an immunology firm, reported significant Q1 2024 financial growth with $398 million in global net product sales, driven by the expansion of its VYVGART product line. The company is on track with regulatory submissions, including an FDA review for CIDP and a new pre-filled syringe format expected to file in Q2 2024. Argenx is advancing its diverse pipeline with multiple programs in registrational trials and expects to deepen its FcRn biology understanding with upcoming Phase 2 data.
For further insights into ARGX stock, check out TipRanks’ Stock Analysis page.